Peptides Blends

TB4, a thymosin β4 fragment, mobilizes actin, boosts vascular growth, and aids healing of tendons, heart, and skin injuries. KPV, an α-MSH tripeptide, enters cells via PepT1, inhibiting NF-κB and STAT3 to reduce gut and skin inflammation. BPC-157, from gastrin, upregulates VEGF and NO, promoting fibroblast migration and angiogenesis, repairing GI mucosa, tendons, and nerves. The Coremend blend (TB500, BPC-157, KPV) synergistically rebuilds tissues, provides chemotactic signals, and blocks inflammation, forming an “anti-inflammatory-migration-regeneration” loop. This enhances soft tissue and mucosal repair, fights fibrosis, and maintains immune balance.

PT 141 (Bremelanotide) is a synthetic cyclic heptapeptide melanocortin receptor agonist derived from α-MSH. It acts on sexual dysfunction by activating central MC3R/MC4R pathways. For males, it improves erectile function through corpus cavernosum smooth muscle relaxation. For females, it enhances sexual desire via CNS-mediated regulation of libido. Its mechanism circumvents traditional PDE5-inhibitor pathways, making it effective for PDE5-resistant cases. PT 141 has demonstrated rapid onset of action within minutes post-administration. Preclinical and clinical evaluations have shown it to be well-tolerated overall.

The peptide will be provided as lyophilized powder to ensure maximum stability.

This triple combination is used to study the multi-level synergistic regulatory mechanisms of the growth hormone axis. Tesamoreli primarily acts on upstream regulatory signals, Ipamorelin stimulates growth hormone release through selective pathways, while CJC-1295 prolongs the duration of endogenous signaling. By covering distinct regulatory nodes, this triad enables systematic investigation of GH secretion rhythms, feedback control, and endocrine system synergism. This combination holds significant model research value for studies on the growth axis, circadian rhythms, and metabolism.